Volume 3, Issue 3, June 2018, Page: 25-29
Clinicopathological and Survival Pattern in Lung Cancer Patients of Different Age Group
Yumkhaibam Sobita Devi, Department of Radiotherapy, Regional Cancer Centre, Regional Institute of medical Science, Imphal, India
Srigopal Mohanty, Department of Radiotherapy, Regional Cancer Centre, Regional Institute of medical Science, Imphal, India
Laishram Jaichand Singh, Department of Radiotherapy, Regional Cancer Centre, Regional Institute of medical Science, Imphal, India
Daffilyne Lyngdoh Nongrum, Department of Radiotherapy, Regional Cancer Centre, Regional Institute of medical Science, Imphal, India
Received: Jun. 12, 2018;       Accepted: Jul. 1, 2018;       Published: Jul. 26, 2018
DOI: 10.11648/j.ijcocr.20180303.12      View  615      Downloads  34
Abstract
Lung cancer is considered as disease of older population with median age of 70 year at diagnosis. The aim of this study was to investigate the clinicopathological and survival pattern in younger and older age lung cancer patients. A retrospective study was carried out for all histopathologically or cytologically confirmed cases of primary lung cancer treated between 2011 and 2015at the Regional Cancer Centre, Imphal, Manipur, India. Cases were grouped into two age groups, i.e. the younger age group (<60 year) and the older age group (≥60 year).Out of the total 432cases of primary lung cancer, 124 were diagnosed at <60year of age with median age of 55 year and 308 patients were diagnosed at ≥60year of age with median age of 70year at diagnosis. Younger age group was found to have significantly lesser number of chronic smokers (p=0.000), lesser history of pulmonary tuberculosis (p=0.019), higher rate of adenocarcinoma (p=0.000), more positive family history (p=0.008), more advanced stage (III & IV) at presentation (p=0.000), greater proportion of patients undergone combined modality of treatment and lesser proportions of patients refused active cancer treatment (p=0.002) as compared to older age group. Response to treatment in terms of median survival (p=0.338) and three year overall survival (p=0.344) was found similar in both the age groups in spite of more advanced stage of the disease at presentation in younger age group, the reasons could be lesser proportion of older age patients got combined modality treatment due to greater comorbidities, poor performance status & greater proportion of older age patients refused active cancer treatment, because of lesser expectation in terms of long term benefit with treatment.
Keywords
Age Variation, Clinicopathology, Lung Cancer, Survival
To cite this article
Yumkhaibam Sobita Devi, Srigopal Mohanty, Laishram Jaichand Singh, Daffilyne Lyngdoh Nongrum, Clinicopathological and Survival Pattern in Lung Cancer Patients of Different Age Group, International Journal of Clinical Oncology and Cancer Research. Vol. 3, No. 3, 2018, pp. 25-29. doi: 10.11648/j.ijcocr.20180303.12
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2(8):706–14.
[2]
Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012; 62(1):10–29.
[3]
Howlader NNA, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute 2013. Available from: http://seer. cancer.gov/csr/1975_2010.
[4]
Neuman HW, Ellis FH, McDonald JR. Bronchogenic carcinoma in persons under 40 years of age. N Engl J Med 1956;254:502–507.
[5]
Bourke W, Milstein D, Giura R et al. Lung cancer in young adults. Chest 1992;102:1723–1729.
[6]
Antkowiak JG, Regal A, Hiroshi T. Bronchogenic carcinoma in patients under age 40. Ann ThoracSurg 1989;47:391–393.
[7]
DeCaro L, Benfield JR. Lung cancer in young persons. J Thorac Cardiovasc Surg 1982;83:372–376.
[8]
Gadgeel SM, Ramalingam S, Cummings G, et al. Lung cancer in patients <50 years of age: the experience of an academic multidisciplinary program. Chest 1999;115:1232-1236.
[9]
Maruyama R, Yoshino I, Yohena T, et al. Lung cancer in patients younger than 40 years of age. J Surg Oncol 2001;77:208–212.
[10]
Mauri D, Pentheroudakis G, Bafaloukos D, et al. Non small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. Anticancer Res 2006;26:3175–3181.
[11]
Skarin AT, Herbst RS, Leong TL, et al. Lung cancer in patients under age 40. Lung Cancer 2001;32:255–264.
[12]
Lara MS, Brunson A, Wun T, et al. Predictors of survival for younger patients less than 50 years of age with non small cell lung cancer (NSCLC): a California Cancer Registry analysis. Lung Cancer 2014;85:264–269.
[13]
Nugent MD, Edney MT, Hammerness PG, et al. Non–small cell lung cancer at the extremes of age: impact on diagnosis and treatment. Ann ThoracSurg 1997;63:193–197.
[14]
Subramanian J, Morgensztern D, Goodgame B, et al. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a Surveillance, Epidemiology, and End Results (SEER) analysis. J Thorac Oncol 2010;5:23–28.
[15]
Thomas A, Chen Y, Yu T, et al. Trends and characteristics of young non-small cell lung cancer patients in the United States. Front Oncol 2015;5:113.
[16]
Kuo C-W, Chen Y-M, Chao J-Y, et al. Non-small cell lung cancer in very young and very old patients. Chest 2000;117:354–357.
[17]
Arnold BN, Thomas DC, Rosen JE, et al. Lung cancer in the very young: treatment and survival in the national cancer data base. J Thorac Oncol 2016;7:1121-1131.
[18]
Makrantonakis PD, Galani E, Harper PG.Non-small cell lung cancer in the elderly. Oncologist 2004;9:556-560.
[19]
Maione P, Rossi A, Sacco PC et al. Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol 2010;2;251-260.
[20]
Owonikoko TK, Ragin CC, Belani CP et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology and end results database. J Clin Oncol 2007; 25:5570-5577.
[21]
Blanchon F, Grivaux M, Zureik M et al. Cohort KBP-2000-CPHG: Evaluation of factors influencing survival in lung cancer. Rev Mal Respir (In French) 2006; 23:165-171.
[22]
Quoix E and Lemarie E. Epidemiological novelties in lung cancer. Rev Mal Respir(In French)2011;28:1048-1058.
[23]
Balducci L, Hardy CL and Lyman GH. Hemopoietic reserve in the older cancer patient, clinical and economic considerations. Cancer Control 2000; 7:539-547.
[24]
Balducci L. Geriatric oncology, challenge for the new century. Eur J Cancer 2000; 36: 1741-1754.
[25]
Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-3218.
[26]
Repetto L, Venturino A, Vercelli M et al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 1998; 82:760-765.
[27]
Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ and Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001; 19:1064-1070.
[28]
Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002:94, 173-181.
[29]
Langer CJ, Vangel M and Schiller J).Age-specific sub analysis of ECOG 1594, fit elderly patients (70-80 yrs) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol 2003; 22:639.
[30]
Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non small cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005;23:190-196.
[31]
Belani CP and Fossella FV. Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin for the first-line treatment of advanced/metastatic non-small cell lung cancer: analyses in elderly patients. Lung Cancer 2003; 41(Suppl 2):S18.
[32]
Ansari RH, Socinski MA, Edelman MJ et al. A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Crit Rev Oncol Hematol 2011; 78:162-171.
Browse journals by subject